Alseksek RK, Ramadan WS, Saleh E, El-Awady R (2022) The role of HDACs in the response of cancer cells to cellular stress and the potential for therapeutic intervention. Int J Mol Sci 23:8141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amelio I, Gostev M, Knight RA, Willis AE, Melino G, Antonov AV (2014) DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis 5(2):e1051

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE (2018) Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anticancer Drugs 29(5):457–465

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basseville A, Violet PC, Safari M, Sourbier C, Linehan WM, Robey RW, Levine M, Sackett DL, Bates SE (2022) A histone deacetylase inhibitor induces acetyl-coA depletion leading to lethal metabolic stress in RAS-pathway activated cells. Cancers (basel) 14:2643

Article  CAS  PubMed  Google Scholar 

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH (2013) PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal 6(268):ra20

Article  PubMed  PubMed Central  Google Scholar 

Bellmunt J, Pons F, Orsola A (2013) Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol 23(5):466–471

Article  PubMed  Google Scholar 

Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R (2020) Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem 27(15):2449–2493

Article  CAS  PubMed  Google Scholar 

Centintas VB, Kucukaslan AS, Kosova B, Tetik A, Selvi N, Gunduz C, Eroglu Z (2012) Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol Int 36(3):261–265

Article  Google Scholar 

Chen HH, Kuo MT (2013) Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res 33(10):4157–4161

CAS  PubMed  PubMed Central  Google Scholar 

Cheshmazar N, Hamzeh-Movehroud M, Charoudeh HN, Hemmati S, Melesina J, Dastmalchi S (2022) Current trends in development of HDAC-based chemotherapeutics. Life Sci 308:120946

Article  CAS  PubMed  Google Scholar 

Chong SX, Jin Y, Au-Yeung SC, To KK (2017) New Pt-NNSO core anticancer agents: structural optimization and investigation of their anticancer activity. J Inorg Biochem 170:34–45

Article  CAS  PubMed  Google Scholar 

Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681

Article  CAS  PubMed  Google Scholar 

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K (2010) IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115:2430–2440

Article  PubMed  Google Scholar 

Eckschlager T, Plch J, Stiboroa M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414

Article  PubMed  PubMed Central  Google Scholar 

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D (2016) Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44:42–50

Article  CAS  PubMed  Google Scholar 

Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE (2011) Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10(7):997–1008

Article  Google Scholar 

Groh T, Hraveta J, Khalil MA, Doktorva H, Eckchlager T, Stiborova M (2015) The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. In J Oncol 47:343–352

CAS  Google Scholar 

Guillotin D, Austin P, Begum R, Freitas MO, Merve A, Brend T, Short S, Marino S, Martin SA (2017) Drug-repositioning screens identify triamterene as a selective drug for the treatment of DNA mismatch repair deficient cells. Clin Cancer Res 23(11):2880–2890

Article  CAS  PubMed  Google Scholar 

He Y, Chen D, Yi Y, Zeng S, Liu S, Li P, Xie H, Yu P, Jiang G, Liu H (2020) Histone deacetylase inhibitor sensitizes ERCC1-high non-small-cell lung cancer cells to cisplatin via regulating miR-149. Mol Ther Oncolytics 17:448–459

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heo EJ, Cho YJ, Cho WC, Hong JE, Jeon HK, Oh DY, Choi YL, Song SY, Choi JJ, Bae DS, Lee YY, Choi CH, Kim TJ, Park WY, Kim BG, Lee JW (2017) Patient-derived xenograft models of epithelial ovarian cancer for preclinical studies. Cancer Res Treat 49(4):915–926

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hontecillas-Prieto L, Flores-Campos R, Silver A, de Alava E, Haiji N, Garcia-Dominguez DJ (2020) Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet 11:578011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ivy KD, Kaplan JH (2013) A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 83(6):1237–1246

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin G, Fu C, Zhao H, Cui K, Chang J, Wong ST (2012) A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 72(1):33–44

Article  CAS  PubMed  Google Scholar 

Karkhanis M, Park JI (2015) Sp1 regulates Raf/MEK/ERK-induced p21CIP1 transcription in TP53-mutated cancer cells. Cell Signal 27(3):479–486

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kilari D, Guancial E, Kim ES (2016) Role of copper transporters in platinum resistance. World J Clin Oncol 7(1):106–113

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Choy ML, Ngo L, Foster SS, Mars PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107:14639–14644

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JJ, Miller JA, Basu S, Kee TV, Loo LH (2018) Building predictive in vitro pulmonary toxicity assays using high-throughput imaging and artificial intelligence. Arch Toxicol 92(6):2055–2075

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6(10):a026831

Article  PubMed  PubMed Central  Google Scholar 

Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z (2016) A survey of current trends in computational drug repurposing. Brief Bioinform 17:2–12

Article  PubMed  Google Scholar 

Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247–1252

Article  CAS  PubMed  Google Scholar 

Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW (2014) The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma. Oncogene 33(47):5415–5423

Article  CAS  PubMed  Google Scholar 

Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F (2019) Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol 32(8):1469–1486

Article  CAS  PubMed  Google Scholar 

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U, Frotschl R (2017) Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS ONE 12(7):e0181081

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

Article  PubMed  Google Scholar 

Singh BN, Zhang G, Hwa YL, Li JP, Dowdy SC, Jiang SW (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10(6):935–954

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh T, Kaur P, Singh P, Singh S, Munshi A (2022) Differential molecular mechanistic behavior of HDACs in cancer progression. Med Oncol 39(11):171